Bruce R. Russell

2 papers in the library · 7 citations · publishing 2016-2024

Papers

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.

Trials May 21, 2024 Chiranth Bhagavan, Paul Glue, Will Evans et al. 7 citations

A clinical trial will test whether MDMA-assisted therapy can reduce anxiety and depression in people with advanced-stage cancer. Up to 32 participants will be randomly assigned to receive either 120 mg of MDMA (with an optional 60 mg supplement) or a low dose of methylphenidate as a psychoactive control, each combined with therapeutic support sessions. The study will track mood, anxiety, quality of life, and other measures for up to 12 months. This research aims to establish the safety and effectiveness of a novel treatment for mental suffering in patients with life-threatening illness.

DOI: 10.1186/s13063-024-08174-x Full text Anxiety Depression Psychedelic therapy 3,4-Methylenedioxymethamphetamine MDMA +8

Acute effects of BZP, TFMPP and the combination of BZP and TFMPP in comparison to dexamphetamine on an auditory oddball task using electroencephalography: a single-dose study

Psychopharmacology March 1, 2016 HeeSeung Lee, Grace Y. Wang, Louise E. Curley et al.

A single oral dose of either TFMPP or dexamphetamine significantly reduced the P300 amplitude, a measure of brain electrical activity related to attention and information processing. A similar trend was observed with BZP alone. However, the combination of BZP and TFMPP had no effect on P300 amplitude. Neither P300 latency nor reaction time was affected by any drug treatment, nor were earlier sensory components P100 and P200. The findings suggest that BZP and TFMPP, but not their combination, affect auditory sensory-evoked P300 potential in a manner similar to dexamphetamine.

DOI: 10.1007/s00213-015-4165-x Full text Bzp Tfmpp Human erp P300